CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
RxMine aims to improve treatment for major depressive disorder by using advanced stem cell technology and machine learning to identify the most effective antidepressant for individual patients. This personalized approach seeks to reduce the trial-and-error method currently used in prescribing medications, ultimately en…
Major depressive disorder affects around 300M people globally and is the second leading cause of disability, with up to 14 years of life lost per patient and an annual burden of up to 170 billion to the EU.
Despite numerous available drugs, 75% of patients do not receive adequate treatment, 63% try multiple medications, and a third do not respond after two rounds of treatment.
This trial-and-error approach is destructive to patients, time-consuming for physicians and expensive to health c…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
